Scottish technology company iGii has announced a multi-million pound partnership with health monitoring company Prymexa to develop an at-home toolkit for early perimenopause detection. The collaboration aims to address a significant gap in menopause awareness and monitoring, with 60% of women under 40 reporting they don’t feel informed about this life stage.
The toolkit will leverage iGii’s proprietary Gii technology, a sustainable carbon nanomaterial that provides a more sensitive alternative to traditional carbon and metal-based sensors. This technology could enable more accurate assessment of menopause symptoms through wearable devices and sensors for at-home monitoring.
“Menopause receives a fraction of the investment compared to other medical fields, yet half the population will experience it and demand for effective management solutions is growing exponentially,” said Sara Pardoe, Chief Executive Officer at Prymexa. “Our research aims to bring individuals closer to a simple, clear understanding of their menopause journey and how to best manage it.”
The technology’s potential extends beyond simple symptom tracking. Early identification of perimenopause could enable more personalized intervention strategies, particularly important given the increased risks of depression, osteoporosis, and cardiovascular disease associated with menopause.
“Gii has the potential to significantly improve point-of-care human diagnostics and make accurate, quick medical results the norm,” explained Jean-Christophe Granier, CEO of iGii. “Its properties provide a more affordable, sustainable, scalable and sensitive sensing platform for high-quality results in labs and at home. This project with Prymexa highlights the real value and potential of Gii and we look forward to working with them to positively impact the lives of those going through the perimenopause period.”
“We are thrilled about this partnership, which promises to transform lives through our extensive research and development efforts,” said David Atkinson, Founder of Prymexa. “By joining forces with iGii, we can enhance the precision and sensitivity of our toolkit, accelerating our product development and ultimately making a significant difference in people’s lives.”
Directors Romy Williams and Sophie Stubbs added: “Prymexa is continuously advancing and solidifying its position in the health monitoring industry. Our partnership with iGii further underscores our commitment to easing the perimenopausal and menopausal journey for individuals. By collaborating, we are enhancing our ability to offer comprehensive, supportive solutions tailored to the unique needs of those experiencing these significant life transitions. We are both thrilled about the incredible benefits our solutions will bring in the coming years.”
While specific details about the toolkit’s features and launch timeline haven’t been disclosed, the collaboration signals increasing investment in innovative solutions for menopause diagnostics and management.
